Literature DB >> 16990356

The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.

H Senzaki1.   

Abstract

Kawasaki disease is an acute inflammatory syndrome that takes the form of systemic vasculitis, and predominantly affects children. Important complications of this disease are coronary artery dilation and aneurysm formation. Recent studies indicate that Kawasaki disease patients have elevated expression, activity, or protein levels of matrix metalloproteinases (MMPs), and suggest that imbalances in MMPs or MMP/tissue inhibitor of MMP (TIMP) play important pathophysiological roles in the development of coronary artery lesions in this disease. However, it remains unclear whether MMP activities at the site of coronary artery lesions are indeed increased. Further studies on the effects of MMP inhibition on coronary outcome are needed to define the roles of MMPs and TIMPs in the formation of coronary artery lesions in Kawasaki disease; findings of such studies may support the use of MMP inhibitors for the prevention of coronary artery complications in patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990356      PMCID: PMC2066006          DOI: 10.1136/adc.2005.087437

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  43 in total

1.  Arterial hemodynamics in patients after Kawasaki disease.

Authors:  Hideaki Senzaki; Chen-Huan Chen; Hirotaka Ishido; Satoshi Masutani; Tamotsu Matsunaga; Mio Taketazu; Toshiki Kobayashi; Nozomu Sasaki; Shunei Kyo; Yuji Yokote
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

Review 2.  The immunopathogenesis and management of Kawasaki syndrome.

Authors:  D Y Leung; P M Schlievert; H C Meissner
Journal:  Arthritis Rheum       Date:  1998-09

3.  Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II.

Authors:  H Senzaki; Y A Gluzband; P H Pak; M T Crow; J S Janicki; D A Kass
Journal:  Circ Res       Date:  1998-03-09       Impact factor: 17.367

4.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm.

Authors:  D G Peters; A Kassam; P L St Jean; H Yonas; R E Ferrell
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

5.  Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis.

Authors:  T Matsuyama
Journal:  Pediatr Int       Date:  1999-06       Impact factor: 1.524

6.  Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms.

Authors:  S Yoon; G Tromp; S Vongpunsawad; A Ronkainen; T Juvonen; H Kuivaniemi
Journal:  Biochem Biophys Res Commun       Date:  1999-11-19       Impact factor: 3.575

7.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.

Authors:  P Carmeliet; L Moons; R Lijnen; M Baes; V Lemaître; P Tipping; A Drew; Y Eeckhout; S Shapiro; F Lupu; D Collen
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

8.  Corticosteroids in the treatment of the acute phase of Kawasaki disease.

Authors:  M Shinohara; K Sone; T Tomomasa; A Morikawa
Journal:  J Pediatr       Date:  1999-10       Impact factor: 4.406

9.  Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.

Authors:  E Allaire; D Hasenstab; R D Kenagy; B Starcher; M M Clowes; A W Clowes
Journal:  Circulation       Date:  1998-07-21       Impact factor: 29.690

10.  Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B.

Authors:  M Bond; R P Fabunmi; A H Baker; A C Newby
Journal:  FEBS Lett       Date:  1998-09-11       Impact factor: 4.124

View more
  34 in total

1.  Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.

Authors:  Govindarajan Rajagopalan; Ashenafi Y Tilahun; Yan W Asmann; Chella S David
Journal:  Physiol Genomics       Date:  2009-03-31       Impact factor: 3.107

Review 2.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 3.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

4.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.

Authors:  Youngho Lee; Daiko Wakita; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Ganghua Huang; Thomas J A Lehman; Michael C Fishbein; Hal M Hoffman; Timothy R Crother; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

Review 5.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

6.  The Balance of Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Autoimmune Inner Ear Disease Patients.

Authors:  Logan Eisner; Andrea Vambutas; Shresh Pathak
Journal:  J Interferon Cytokine Res       Date:  2017-07-11       Impact factor: 2.607

7.  A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants.

Authors:  Karl G Sylvester; Xuefeng B Ling; G Y Liu; Zachary J Kastenberg; Jun Ji; Zhongkai Hu; Sihua Peng; Ken Lau; Fizan Abdullah; Mary L Brandt; Richard A Ehrenkranz; Mary Catherine Harris; Timothy C Lee; Joyce Simpson; Corinna Bowers; R Lawrence Moss
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

8.  Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Authors:  Chrysanthos Symeonidis; Eleni Papakonstantinou; Asimina Galli; Ioannis Tsinopoulos; Asimina Mataftsi; Spyridon Batzios; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-20       Impact factor: 3.117

9.  Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children.

Authors:  Young Mi Hong; Hyun-Seung Jin; In Sook Park; Soo-Jong Hong
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

Review 10.  Systemic vasculitis in childhood.

Authors:  Abraham Gedalia; Raquel Cuchacovich
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.